Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Buys 6,387 Shares of Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. purchased 6,387 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average cost of $24.90 per share, for a total transaction of $159,036.30. Following the completion of the purchase, the insider directly owned 6,372,170 shares of the company’s stock, valued at approximately $158,667,033. This represents a 0.10% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.81 per share, with a total value of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. bought 9,906 shares of Hemab Therapeutics stock. The shares were acquired at an average cost of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Price Performance

Shares of Hemab Therapeutics stock traded down $0.19 during trading on Thursday, hitting $28.37. The company’s stock had a trading volume of 155,514 shares, compared to its average volume of 305,945. Hemab Therapeutics Holdings, Inc. has a 52 week low of $23.00 and a 52 week high of $36.61.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.